Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Bristol-Myers Squibb
Bristol-Myers Squibb
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Hoffmann-La Roche
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Bristol-Myers Squibb
Taiho Oncology, Inc.
NRG Oncology
Verastem, Inc.
Merck Sharp & Dohme LLC
Arcus Biosciences, Inc.
Eli Lilly and Company
Eli Lilly and Company
Boehringer Ingelheim
Gilead Sciences
Eli Lilly and Company
Pfizer
AstraZeneca
Revolution Medicines, Inc.
AstraZeneca
Hoffmann-La Roche
Shanghai Chest Hospital
Pfizer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
Massachusetts General Hospital
University Medical Center Groningen
Regeneron Pharmaceuticals
Big Ten Cancer Research Consortium
Inhibrx Biosciences, Inc
H. Lee Moffitt Cancer Center and Research Institute
Mayo Clinic
National Cancer Institute (NCI)
Lantern Pharma Inc.
University of Kentucky
Weill Medical College of Cornell University
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Guangzhou JOYO Pharma Co., Ltd
BeiGene
Masonic Cancer Center, University of Minnesota
University Hospital, Essen
University Health Network, Toronto